Prelude Therapeutics Incorporated · NASDAQ:PRLD
INCYTE CORP reported a 9.90% stake in Prelude Therapeutics Incorporated (Schedule 13G)
Event Nov 3, 2025 · Filed Nov 7, 2025
INCYTE CORP reported a 9.90% stake in Prelude Therapeutics Incorporated, 4,372,124 shares, as a passive investor on Nov 3, 2025. Filed Nov 7, 2025 (Schedule 13G).
- Stake
- 9.90%
- Shares
- 4,372,124
- Intent
- Passive
- What changed
- Crossed above 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| INCYTE CORP | 9.90% | 4,372,124 |
Source
Related
- Prelude Therapeutics Incorporated
- Incyte Corp
- Prelude Therapeutics Incorporated shareholders
- Schedule 13G · Soleus Capital Management, L.P. · Jul 8, 2026
- Form 4 · Shah Rajeev M. · Apr 28, 2026
- Schedule 13G · Ra Capital Management, L.P. · Apr 28, 2026
- Form 4 · Bonita David P · Apr 23, 2026
- Form 4 · OrbiMed Genesis GP LLC · Apr 23, 2026